Share Name Share Symbol Market Type Share ISIN Share Description
Omega Dia LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 20.50p 20.00p 21.00p 20.50p 20.50p 20.50p 0 07:45:41
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 12.7 0.7 0.5 41.0 22.29

Omega Diagnostics (ODX) Latest News

More Omega Diagnostics News
Omega Diagnostics Takeover Rumours

Omega Diagnostics (ODX) Share Charts

1 Year Omega Diagnostics Chart

1 Year Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

Intraday Omega Diagnostics Chart

Intraday Omega Diagnostics Chart

Omega Diagnostics (ODX) Discussions and Chat

Omega Diagnostics Forums and Chat

Date Time Title Posts
22/6/201708:18Omega Diagnostics - nicely poised for significant growth69
25/5/201710:47Omega Diagnostics1,773

Add a New Thread

Omega Diagnostics (ODX) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Omega Diagnostics trades in real-time

Omega Diagnostics (ODX) Top Chat Posts

DateSubject
26/6/2017
09:20
Omega Diagnostics Daily Update: Omega Dia is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker ODX. The last closing price for Omega Diagnostics was 20.50p.
Omega Dia has a 4 week average price of 19.38p and a 12 week average price of 19.38p.
The 1 year high share price is 28.25p while the 1 year low share price is currently 15.75p.
There are currently 108,745,669 shares in issue and the average daily traded volume is 2,016 shares. The market capitalisation of Omega Dia is £22,292,862.15.
21/6/2017
08:19
buywell3: To what extent is or has CD4 been the catalyst for the last rise ? That needs answering, I have already posted my thoughts . I think the BOD was extremely premature in informing the market of this product when it was clearly beset by some issues which have dragged on. The share price to date has been held up by a single buyer it seems Which in itself has some risk I also raised the issue re licence .... which I see as another unresolved risk Then there is India which I have not even bothered to look into till the chart resolves itself The share might now rise due to the 'buywell effect'' it happens quite often
25/4/2017
07:58
jeevsje: You won't get the chance to hold for years. Mark my words - this will be sold at roughly 2X to 3X of current share price once CD4 is commercialised.
25/4/2017
07:42
tickboo: A decent RNS and once cd4 is commercialised the share price will be multiples of here and they'll be more cash to develop new products. Am long. Shame I've only got 75,000 but will get some more in the coming weeks ahead of the FY results.
18/4/2017
10:37
jeevsje: The way in which the share price is ticking down might suggest that they are probably in the process of arranging the equity raise prior to the trading update. This would alleviate any concerns about funding but depends what price they get the placing at.
13/4/2017
16:54
longshanks: I "bed 'n' isa'd" a few today. Looks like others are doing the same.The market has been well bid all week so I anticipate a storming run in the share price if we get a good positive update.
07/3/2017
08:56
longshanks: Not sure he is in a hurry - but he clearly has some funds available to invest and he still clearly sees ODX as cheap.When you consider that many of the executive options only vest when the share price has risen above 50p, there is still lots of potential here.
27/1/2017
07:28
rivaldo: Today's RNS confirming that IDH wants an "enlarged" distribution relationship with ODX is a vote of confidence in the company's products: Http://www.investegate.co.uk/omega-diagnostics-gp--odx-/rns/update-on-discussions-with-ids/201701270700062449V/ There doesn't appear to be any froth at all in the share price from anyone expecting a multi-million pound sale of the allergy business, so I'd hope that no-one would be too disappointed.
23/1/2017
16:12
hyperboreus: Looking like you might get your wish longshanks re 16.5p Been having a really in depth look at all the director share options and the first tranche issued to Evans, Shepherd and Harbinson with exercise price at 19p expire on 10 December 2018 having been issued on 10 December 2008. I am sure they would have been expecting ODX's share price to be much higher by now over 9 years later as it has gone nowhere really since then. The next sizeable batch issued to Shepherd, Harbinson and Grewal with exercise price at 14.5p expire on 5 July 2022 but share price must be 25p or higher. Interestingly David Evans doesn't have any other options other than the one which expires next December, but having said that he was very generously 'allowed' to purchase 2,760,134 shares at 12p on 17 Dec 2010 in a private placing in relation to the purchase of the ALLERGOPHARMA IVD BUSINESS. His average share price purchase by the way is 12.81p, Jag Grewal's is 19.92p, not so easy to work out Harbinson's and Shepherd's as they they were directors in ODX before reverse takeover in 2006 but my best guess for Harbinson is 12.88p and 9.38p for Shepherd. My average share price in ODX has gone up significantly from my first purchase in April 2012 at 10.25p but at just over 16p I am still confident that exciting times are ahead, just not sure how long I might have to wait like the rest of us!
13/1/2017
16:58
hyperboreus: Interesting 30 mins or so researching Mr Sneller, his current holdings as far as I am aware are: Bango (BGO) 3,000,000 shares = 4.68% Bioquell (BQE) minimal holding Hayward Tyler(HAYT) 3,625,000 shares = 6.55% Omega (ODX) 11,453,488 shares = 10.53% Plant Impact (PIM) 2,493,000 shares = under 3% Prior to 26 October 2016 he held 2,320,000 shares in Cyprotex a Bioscience operation who received a recommended offer of 160p from Evotec, a GERMAN 'Drug Discovery' operation. Since he pocketed £3,712,000 from the takeover of Cyprotex he appears to have acquired a significant stake in Hayward Tyler and continued to increase his holding in Omega. What is really interesting is that Sneller started to build his stake in Cyprotex in 2009 when the share price was around 5p and incidentally was still around those levels in early 2014. PATIENCE IS CLEARLY HIS WATCHWORD!
09/6/2016
09:18
gary38: Omega Diagnostics Group PLC Holding(s) in CompanyIntraday Omega Diagnostics ChartIntraday Omega Diagnostics Chart09/06/2016 8:07amUK Regulatory (RNS & others)TIDMODXRNS Number : 7240AOmega Diagnostics Group PLC09 June 2016TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) --------------------------------------------------------------------------------------------- 1. Identity of the issuer or Omega Diagnostics Group the underlying issuer plc of existing shares to which voting rights are attached: (ii) --------------------------------------------------------------- ---------------------------- 2 Reason for the notification (please tick the appropriate box or boxes): --------------------------------------------------------------------------------------------- An acquisition or disposal of voting rights X ------------------------------------------------------------------- ------------------------ An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ------------------------------------------------------------------- ------------------------ An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ------------------------------------------------------------------- ------------------------ An event changing the breakdown of voting rights ------------------------------------------------------------------- ------------------------ Other (please specify): --------------------------------------------------------- -------- ------------------------ 3. Full name of person(s) Richard Edgar Sneller subject to the notification obligation: (iii) ----------------------------------------------------------- -------------------------------- 4. Full name of shareholder(s) (if different from 3.):(iv) ----------------------------------------------------------- -------------------------------- 5. Date of the transaction 8(th) June 2016 and date on which the threshold is crossed or reached: (v) ----------------------------------------------------------- -------------------------------- 6. Date on which issuer 8(th) June 2016 notified: ----------------------------------------------------------- -------------------------------- 7. Threshold(s) that is/are >6% crossed or reached: (vi, vii) ----------------------------------------------------------- -------------------------------- 8. Notified details: ---------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares (viii, ix)---------------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE ------------- -------------------------------- --------------------------------------------------------------------- Number Number Number Number of % of voting of of of shares voting rights (x) Shares Voting rights Rights ------------- --------------- --------------- -------------- -------------------------- ------------------------- Direct Direct Indirect Direct Indirect (xi) (xii) ------------- ----------- ----------- -------------- ------------ ------------ ------------ ----------- GB00B1VCP282 6,515,000 6,515,000 6,765,000 6,765,000 6.22% ------------- --------------- --------------- -------------- ------------ ------------ ------------ ----------- B: Qualifying Financial Instruments ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Expiration Exercise/ Number of voting % of voting financial date Conversion rights that rights instrument (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. ----------------- ------------- ------------------------------- ---------------------------- --------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights (xix, instrument (xvii) period refers to xx) (xviii) --------------- ------------- ------------- ---------------- ---------------------------- ----------------------- Nominal Delta --------------- ------------- ------------- ---------------- ---------------------------- ------------ --------- Total (A+B+C) ---------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights ------------------------------------------------- ------------------------------------------------------------------- 6,765,000 6.22% ------------------------------------------------- ------------------------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) ------------------------------------------------------------------------------- Proxy Voting: ------------------------------------------------------------------------------- 10. Name of the proxy holder: ------------------------------------------------------------- ---------------- 11. Number of voting rights proxy holder will cease to hold: ------------------------------------------------------------- ---------------- 12. Date on which proxy holder will cease to hold voting rights: ------------------------------------------------------------- ---------------- 13. Additional information: ------------------------------------------------------------- ---------------- 14. Contact name: Richard Sneller ------------------------------------------------------------- ---------------- 15. Contact telephone number: 0131 275 2198 ------------------------------------------------------------- ---------------- This information is provided by RNSThe company news service from the London Stock ExchangeENDHOLUKRWRNSANRRR(END) Dow Jones NewswiresJune 09, 2016 04:07 ET (08:07 GMT)Omega Diagnostics Share Price TodayOmega Diagnostics Share Price ChartOmega Diagnostics Share ChatOmega Diagnostics NewsOmega Diagnostics Share Price HistoryOmega Diagnostics DividendOmega Diagnostics TradesOmega Diagnostics Level 2Add Omega Diagnostics to WatchlistAdd Omega Diagnostics to your PortfolioOmega Diagnostics Share Price AlertSwitch to Desktop View By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & ConditionsShare and Investment Glossary Investment Warning Copyright © 1999 - 2016 Cookie and Privacy Policy
Omega Diagnostics share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20170626 12:22:56